NO20072705L - Alfa-tymosinpeptider som cancervaksineadjuvanser - Google Patents

Alfa-tymosinpeptider som cancervaksineadjuvanser

Info

Publication number
NO20072705L
NO20072705L NO20072705A NO20072705A NO20072705L NO 20072705 L NO20072705 L NO 20072705L NO 20072705 A NO20072705 A NO 20072705A NO 20072705 A NO20072705 A NO 20072705A NO 20072705 L NO20072705 L NO 20072705L
Authority
NO
Norway
Prior art keywords
cancer vaccine
alpha
subject
vaccine adjuvants
thymosin peptides
Prior art date
Application number
NO20072705A
Other languages
English (en)
Norwegian (no)
Inventor
Alfred R Rudolph
Gustavo Antonio Moviglia
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20072705L publication Critical patent/NO20072705L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20072705A 2004-12-06 2007-05-29 Alfa-tymosinpeptider som cancervaksineadjuvanser NO20072705L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (1)

Publication Number Publication Date
NO20072705L true NO20072705L (no) 2007-09-05

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072705A NO20072705L (no) 2004-12-06 2007-05-29 Alfa-tymosinpeptider som cancervaksineadjuvanser

Country Status (15)

Country Link
US (1) US20100092499A1 (de)
EP (1) EP1835931A4 (de)
JP (1) JP2008523067A (de)
KR (1) KR20070086663A (de)
CN (1) CN101072582B (de)
AU (1) AU2005314271B2 (de)
BR (1) BRPI0518571A2 (de)
CA (1) CA2588685A1 (de)
EA (1) EA015510B1 (de)
IL (1) IL183264A (de)
MX (1) MX2007006717A (de)
NO (1) NO20072705L (de)
NZ (1) NZ555571A (de)
UA (1) UA90493C2 (de)
WO (1) WO2006062917A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708168A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2427213B1 (de) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha-thymosin-peptide als impfstoffverstärker
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
EP2804626B1 (de) * 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologer krebszellenimpfstoff
US20150031617A1 (en) * 2012-03-08 2015-01-29 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
TWI683667B (zh) * 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
PL354093A1 (en) * 1999-06-30 2003-12-29 Corixa Corporationcorixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
BR0213554A (pt) * 2001-10-26 2004-10-26 Rhode Island Hospital Timosina para aumento da imunização genética
MXPA05000078A (es) * 2002-06-28 2005-04-11 Sciclone Pharmaceuticals Inc Metodo para sobre-regular la expresion de antigeno tumoral utilizando timalfasina, y composiciones y usos.
BRPI0408892A (pt) * 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
EP2633866A3 (de) * 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
EP2427213B1 (de) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha-thymosin-peptide als impfstoffverstärker

Also Published As

Publication number Publication date
CN101072582B (zh) 2012-06-27
CN101072582A (zh) 2007-11-14
IL183264A (en) 2010-12-30
BRPI0518571A2 (pt) 2008-11-25
JP2008523067A (ja) 2008-07-03
IL183264A0 (en) 2007-09-20
UA90493C2 (ru) 2010-05-11
EP1835931A4 (de) 2008-12-17
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
EA015510B1 (ru) 2011-08-30
AU2005314271A1 (en) 2006-06-15
NZ555571A (en) 2009-02-28
CA2588685A1 (en) 2006-06-15
AU2005314271B2 (en) 2011-06-16
EP1835931A2 (de) 2007-09-26
KR20070086663A (ko) 2007-08-27
MX2007006717A (es) 2007-08-06
WO2006062917A3 (en) 2006-11-16
EA200701166A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
MX353165B (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
MX2009009342A (es) Metodo novedoso y composiciones.
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
PE20121393A1 (es) Analogo peptidico de oxintomodulina
WO2006066214A3 (en) Use of flagellin in the immunotherapy of yersinia pestis
NZ534919A (en) Bioactive keratin peptides
EP2526966A3 (de) Mit Herpes-simplex-Virus kombinierte Untereinheitsimpfstoffe und Verfahren zu deren Verwendung
ATE523205T1 (de) Prime-boost-impfstoffe gegen malaria
EP3533461A3 (de) Von prame abstammende peptide und immunogene zusammensetzungen damit
WO2006120038A3 (en) Use of native peptides and their optimized derivatives for vaccination
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
RU2013131089A (ru) Пептиды тем8 и содержащие их вакцины
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
SG162791A1 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
EP1932915A3 (de) Materialien und Verfahren im Zusammenhang mit verbesserten Impfstrategien
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
ATE484290T1 (de) Peptid mit antitumoraler wirkung
WO2003093298A3 (en) Immunogenic peptides
NO20061542L (no) P185neu-Kodende DNA samt terapeutiske anvendelser derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application